Arcus Biosciences (RCUS) Revenue (2017 - 2026)

Arcus Biosciences' Revenue history runs 10 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• In Q1 2026, Revenue fell 39.29% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $236.0 million (up 67.38% YoY), while the FY2025 annual figure was $247.0 million, down 4.26% from the prior year.
• Revenue was $17.0 million for Q1 2026 at Arcus Biosciences, down from $33.0 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $160.0 million in Q2 2025 to a low of $14.0 million in Q4 2023.
• Historically, Revenue has averaged $43.2 million across 5 years, with a median of $29.0 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Revenue slumped 90.41% in 2022, then jumped 480.0% in 2024.
• A 5-year view of Revenue shows it stood at $34.0 million in 2022, then plunged by 58.82% to $14.0 million in 2023, then surged by 85.71% to $26.0 million in 2024, then gained by 26.92% to $33.0 million in 2025, then plunged by 48.48% to $17.0 million in 2026.
• The last three Revenue figures came in at $17.0 million (Q1 2026), $33.0 million (Q4 2025), and $26.0 million (Q3 2025), per Business Quant data.